Top

Comparison of outcomes of myelofibrosis patients undergoing 1st matched sibling donor (MSD) allo- HCT receiving either PTCy based or other “conventional GVHD prophylaxis”

Chronic Malignancies Working Party (CMWP)
Study type:
Retrospective Studies
Study number:
42201096
Type of treatment:
Allogeneic
Allogeneic - Related
Diseases:
Myeloproliferative Neoplasm (MPN)
Short title:
PTCy vs standard GvHD prophylaxis for MSD in myelofibrosis
Primary objective:
To compare graft-versus-host disease-relapse free survival (GRFS) in the PTCY vs other GvHD prophylaxis in patients transplanted for myelofibrosis
Key inclusion criteria:
Patient’s age more than 18 years
Myelofibrosis (primary and post-ET/PV)
First allo-transplant from a matched sibling donor with the use of peripheral blood or bone marrow as stem cell source
Transplant period 2014-2022
Country:
All EBMT member countries
Principal investigator:
Patrizia Chiusolo
EBMT Study coordinator:
Linda Koster
Study coordinator email:
cmwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
Investigators
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results